FOLH1 and neoplasm: Patients with increased PSMA expression on pretherapeutic PET (defined by the average mean standardized uptake value of all tumor lesions [SUV<sub>mean</sub>]) had a higher response rate (86%; 6 out of 7) compared to those with decreased SUV<sub>mean</sub> (31%; 5 out of 16).